AxoGen, Inc. Aktie News

Axogen, Inc. ( AXGN ) Q3 2025 Earnings Call October 29, 2025 8:00 AM EDT Company Participants Michael Dale - President, CEO & Director Lindsey Hartley - Chief Financial Officer Rick Ditto Jens Schroeder Kemp - Chief Marketing Officer Conference Call Participants Christopher Pasquale - Nephron Research LLC Michael Sarcone - Jefferies LLC, Research Division Caitlin Cronin - Canaccord Genuity Corp...

Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million

LOS ANGELES--(BUSINESS WIRE)--Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN.

Shares of Axogen plunged Monday after the FDA delayed the expected approval date for the company's nerve graft product.

ALACHUA, Fla. and TAMPA, Fla.

Axogen is compounding business capital at increasing returns which was reflected in Q2 earnings. The stock remains in a down-trend with investors compressing multiples paid on capital invested into the business. The range of potential outcomes remains broad which coincides with historical trends seen in market for this name.

Axogen (AXGN) Q2 Revenue Jumps 18%

Axogen, Inc. (NASDAQ:AXGN ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants Jens Schroeder Kemp - Chief Marketing Officer Lindsey Hartley - Chief Financial Officer Michael D. Dale - President, CEO & Director Rick Ditto - Corporate Participant Conference Call Participants Caitlin Cronin - Canaccord Genuity Corp., Research Division Christopher Thomas Pasquale - Nep...